Oasmia Pharmaceutical (VIVE)
Free
No email, no account, no signup.
Pulling latest news for Oasmia Pharmaceutical…
Bull
Bear
Want the why behind the signal? Get the deep 4-model report — full bull/bear, dated catalysts, dilution risk, weekly refresh. $4.99.
Get the deep 4-model report – $4.99
Signal
NEUTRAL
Sentiment
3/10
Risk
8/10
Get full analysis with Bull/Bear case, catalysts, and risk analysis
Order analysis – $4.99
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Sentiment remains negative, centered on dilution, micro-cap risk and the reverse split, but is slightly more wait-and-see after financing/capital actions and study execution were confirmed.
Exchange
Nasdaq Stockholm
Type
Biotech
Sector
Oncology drug development (human and veterinary)
Market Cap
$8M
Market sentiment
Sentiment remains negative, centered on dilution, micro-cap risk and the reverse split, but is slightly more wait-and-see after financing/capital actions and study execution were confirmed.
Why NEUTRAL ?
The previously 'imminent report/AGM' catalyst has now passed, but the reverse split decision and issuance mandate increase the likelihood of further capital actions. With zero revenues and Cantrixil still in early-stage work, binary execution risk remains high; the next clearer datapoints are continued study progress and the H1/Q2 report.
- Hold/wait with a small watch position; avoid adding until clearer study data or improved funding visibility after the split is implemented and any potential new issuance is clarified.
Recent News
- Since 2026-04-06, Vivesto (formerly Oasmia) released Q1 2026 (7 May 2026) showing continued zero revenue and operating result around -SEK 6.8m. The AGM in May approved a 1:100 reverse split, a share capital reduction to reclassify to distributable equity, and an authorization for the board to issue shares/warrants/convertibles. The company also stated that the first dogs were dosed in the Cantrixil PK/tox study.
Bull case
- **May 2026 report/AGM** may clarify cash position and strategy
- **Reverse split** could reduce “penny stock” stigma and improve trading
- **Study progress** headlines can drive short-term upside volatility
Unlock to read more →
Bear case
- **Reverse splits** are often perceived negatively in microcap biotech
- Continued **near-zero revenue** and losses may pressure the share price
- Low liquidity and weak sentiment can amplify drawdowns
Unlock to read more →
Catalysts
15 Jun 2026 — Paccal Vet: pilot data (H1 2026)
Dilution Risk
Assessment: High
Order analysis – $4.99
Save hours of research. $4.99.
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Want to read the full analysis?
Order a fresh analysis of Oasmia Pharmaceutical – ready in your inbox in 5–15 minutes.
- Signal + risk + sentiment
- Bull/Bear case + triggers
- Catalysts with dates
- Saved as a webpage in your account
- Ready in 5–15 min (email when ready)
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Fact-based analysis
Updated weekly
No commitment period
The information on this page does not constitute investment advice. AI-generated analyses may contain errors. Always conduct your own research before making investment decisions. Firelda.ai is not responsible for any potential losses.